PA8536001A1 - Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b - Google Patents

Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b

Info

Publication number
PA8536001A1
PA8536001A1 PA20018536001A PA8536001A PA8536001A1 PA 8536001 A1 PA8536001 A1 PA 8536001A1 PA 20018536001 A PA20018536001 A PA 20018536001A PA 8536001 A PA8536001 A PA 8536001A PA 8536001 A1 PA8536001 A1 PA 8536001A1
Authority
PA
Panama
Prior art keywords
ring
alfa
compounds
quinazolona
antagonists
Prior art date
Application number
PA20018536001A
Other languages
English (en)
Inventor
Cyrus Kephra Becker
Chris Richard Melville
Joan Marie Caroon
Fernando Padilla
Juerg Roland Pfister
Xiaoming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8536001A1 publication Critical patent/PA8536001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

LA INVENCION SE REFIERE A COMPUESTOS QUE SON EN GENERAL ANTAGONISTAS DE ADRENOCEPTORES ALFA-1A/B Y SE AJUSTAN A LA FORMULA GENERAL EN LA QUE Z ES -C(O)- o -S (O)2-, X ES CARBONO O NITROGENO, Y ES CARBONO Y X-Y CONSIDERADOS JUNTOS SON DOS ATOMOS CONTIGUOS AL ANILLO A, DICHO ANILO ES UN ANILLO AROMATICO FUSIONADO DE CINCO O SEIS ATOMOS POR ANILLO QUE INCORPORA EVENTUALMENTE UNO DE LOS DOS HETEROATOMOS POR ANILLO, ELEGIDOS ENTRE N, O Y S; Y LOS DEMAS SUSTITUYENTES TIENEN LOS SIGNIFICADOS DEFINIDOS EN LA DESCRIPCION; O A SUS ISOMEROS INDIVIDUALES, LAS MEZCLAS RACEMICAS O NO RACEMICAS DE ISOMEROS, O A LAS SALES O SOLVATOS FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. LA INVENCION SE REFIERE ADEMAS A LAS COMPOSICIOONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTOS, A LOS METODOS PARA LA OBTENCION DE LOS MISMOS Y AL USO DE DICHOS COMPUESTOS COMO PRINCIIOS ACTIVOS TERAPEUTICOS.
PA20018536001A 2001-01-02 2001-12-27 Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b PA8536001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25933701P 2001-01-02 2001-01-02
US32526701P 2001-09-27 2001-09-27

Publications (1)

Publication Number Publication Date
PA8536001A1 true PA8536001A1 (es) 2002-08-29

Family

ID=26947245

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018536001A PA8536001A1 (es) 2001-01-02 2001-12-27 Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b

Country Status (16)

Country Link
EP (1) EP1363899B1 (es)
JP (1) JP4031363B2 (es)
KR (1) KR100554813B1 (es)
CN (1) CN1237060C (es)
AR (1) AR035775A1 (es)
AT (1) ATE295362T1 (es)
BR (1) BR0116662A (es)
CA (1) CA2432578C (es)
DE (1) DE60110844T2 (es)
ES (1) ES2241891T3 (es)
MX (1) MXPA03005854A (es)
PA (1) PA8536001A1 (es)
PE (1) PE20020735A1 (es)
UY (1) UY27109A1 (es)
WO (1) WO2002053558A1 (es)
ZA (1) ZA200305038B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
CA2530312A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Arylamine-substituted quinazolinone compounds
RU2006102867A (ru) * 2003-07-02 2007-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 5-замещенного хиназолинона
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
CN101336230B (zh) * 2005-11-24 2011-11-23 橘生药品工业株式会社 用于治疗输尿管结石病的药物
US8653091B2 (en) 2007-04-02 2014-02-18 Evotec Ag Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof
PL2139334T3 (pl) 2007-04-17 2013-11-29 Evotec Ag Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
ES2439255T3 (es) 2007-06-21 2014-01-22 Cara Therapeutics, Inc. Imidazoheterociclos sustituidos
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
WO2015018797A2 (en) * 2013-08-05 2015-02-12 Haplogen Gmbh Antiviral compounds
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR20160095157A (ko) * 2013-12-20 2016-08-10 레이보러토리오스델디알에스티브에스에이 융합 이미다졸릴 유도체, 그의 제조 방법 및 의약으로서의 용도
WO2017201161A1 (en) 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN107434786A (zh) * 2016-05-27 2017-12-05 广东东阳光药业有限公司 苯并咪唑化合物及其制备方法
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
SI3710439T1 (sl) 2017-11-15 2023-06-30 Mirati Therapeutics, Inc., Zaviralci mutacije kras g12c
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
KR20220071193A (ko) 2019-08-29 2022-05-31 미라티 테라퓨틱스, 인크. Kras g12d 억제제
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
CN110950886A (zh) * 2019-12-13 2020-04-03 苏州莱克施德药业有限公司 一种合成1-甲基-咪唑-2-甲酸甲酯衍生物的方法
MX2022007515A (es) 2019-12-20 2022-09-19 Mirati Therapeutics Inc Inhibidores de sos1.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4044136A (en) * 1972-09-09 1977-08-23 Pfizer Inc. Aminoquinazoline therapeutic agents
DE2757925A1 (de) * 1977-12-24 1979-06-28 Bayer Ag Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
AU3555200A (en) * 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators

Also Published As

Publication number Publication date
CN1237060C (zh) 2006-01-18
ES2241891T3 (es) 2005-11-01
CA2432578C (en) 2008-04-01
DE60110844T2 (de) 2006-01-12
ZA200305038B (en) 2004-09-27
DE60110844D1 (de) 2005-06-16
WO2002053558A1 (en) 2002-07-11
CN1484640A (zh) 2004-03-24
CA2432578A1 (en) 2002-07-11
JP4031363B2 (ja) 2008-01-09
KR100554813B1 (ko) 2006-02-22
PE20020735A1 (es) 2002-08-21
EP1363899B1 (en) 2005-05-11
KR20030063490A (ko) 2003-07-28
UY27109A1 (es) 2002-07-31
AR035775A1 (es) 2004-07-14
ATE295362T1 (de) 2005-05-15
EP1363899A1 (en) 2003-11-26
MXPA03005854A (es) 2003-09-10
BR0116662A (pt) 2003-09-23
JP2004519454A (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
PA8536001A1 (es) Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
UY27322A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
AR032136A1 (es) Compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
UY27516A1 (es) Bencimidazoles
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
CR7013A (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
UY26968A1 (es) Agentes terapéuticos
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
UY28572A1 (es) Compuestos novedosos
CU23413B7 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
ES2174579T3 (es) Nuevos derivados benzotiofenicos, benzofuranicos e indolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
CY1110904T1 (el) Φαρμακευτικως ενεργα παραγωγα βενζοσουλφοναμιδιου ως αναστολεις πρωτεϊνικων κινασων jun
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PA8589601A1 (es) Derivados de indazol como antagonistas del crf
AR045156A1 (es) Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.